Bicycle Therapeutics (BCYC) News Today $20.36 -0.12 (-0.59%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Bicycle Therapeutics plc (NASDAQ:BCYC) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine analysts that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and seven have issued a buy recoNovember 21 at 2:27 AM | marketbeat.comB. Riley Predicts Lower Earnings for Bicycle TherapeuticsNovember 21 at 1:35 AM | americanbankingnews.comB. Riley Expects Weaker Earnings for Bicycle TherapeuticsBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - B. Riley lowered their FY2024 EPS estimates for Bicycle Therapeutics in a research report issued on Monday, November 18th. B. Riley analyst K. Patel now anticipates that the company will earn ($2.83) per share for the year, down from their prNovember 20 at 6:39 AM | marketbeat.comPrincipal Financial Group Inc. Takes $10.03 Million Position in Bicycle Therapeutics plc (NASDAQ:BCYC)Principal Financial Group Inc. purchased a new position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 443,141 shareNovember 19 at 3:24 AM | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Short Interest UpdateBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 3,270,000 shares, an increase of 12.0% from the October 15th total of 2,920,000 shares. Based on an average daily volume of 403,700 shares, the short-interest ratio is presently 8.1 days.November 16, 2024 | marketbeat.comBicycle Therapeutics' SWOT analysis: innovative platform fuels stock's potentialNovember 15, 2024 | uk.investing.comBicycle Therapeutics' SWOT analysis: innovative platform fuels stock's potentialNovember 15, 2024 | uk.investing.comWichita looking for public input on Draft Bicycle PlanNovember 14, 2024 | msn.comTravis Alvin Thompson Sells 6,256 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) StockNovember 14, 2024 | insidertrades.comIs Bicycle Therapeutics plc (BCYC) Top Performing European Stock Heading into 2025?November 14, 2024 | msn.comBicycle Therapeutics to Participate in the Jefferies London Healthcare ConferenceNovember 12, 2024 | finance.yahoo.comStephens & Co. Initiates Coverage of Bicycle Therapeutics plc - Depositary Receipt () (BCYC) with Equal-Weight RecommendationNovember 9, 2024 | msn.comBicycle Therapeutics (NASDAQ:BCYC) Earns Equal Weight Rating from Analysts at StephensStephens began coverage on Bicycle Therapeutics in a research note on Friday. They set an "equal weight" rating and a $25.00 target price for the company.November 8, 2024 | marketbeat.comStephens sees ‘uphill battle’ for Bicycle Therapeutics, starts at Equal WeightNovember 7, 2024 | markets.businessinsider.comBicycle Therapeutics: Looking Again At An Intriguing Developmental ConcernNovember 7, 2024 | seekingalpha.comBicycle Therapeutics plc (NASDAQ:BCYC) Shares Sold by AlphaCentric Advisors LLCAlphaCentric Advisors LLC lessened its position in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 37.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 37,500 shares of the company's stock after selling 22,500 shares during the period. AlphaCentric AdviNovember 5, 2024 | marketbeat.comBicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagNovember 3, 2024 | finance.yahoo.comBicycle Therapeutics: Buy Recommendation Backed by Strong Financials and Promising Pipeline ProgressNovember 3, 2024 | markets.businessinsider.comBicycle Therapeutics: Promising Q3 Results and Business ProgressNovember 2, 2024 | markets.businessinsider.comBicycle Therapeutics Faces Strategic Risks from Concentrated Shareholder InfluenceNovember 2, 2024 | markets.businessinsider.comBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | businesswire.comBicycle Therapeutics (NASDAQ:BCYC) Earns Outperform Rating from Royal Bank of CanadaRoyal Bank of Canada reiterated an "outperform" rating and set a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday.November 1, 2024 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Releases Earnings Results, Beats Expectations By $0.06 EPSBicycle Therapeutics (NASDAQ:BCYC - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.74) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.06. Bicycle Therapeutics had a negative net margin of 417.88% and a negative return on equity of 32.80%. The business had revenue of $2.68 million during the quarter, compared to analyst estimates of $6.82 million. During the same quarter in the previous year, the business posted ($1.26) EPS. Bicycle Therapeutics's quarterly revenue was down 50.0% on a year-over-year basis.November 1, 2024 | marketbeat.comBicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial ResultsNovember 1, 2024 | businesswire.comBicycle Therapeutics: Buy Rating Backed by Promising Pipeline Potential Despite Earnings DiscrepanciesNovember 1, 2024 | markets.businessinsider.comBicycle Therapeutics: Strategic Advancements and Financial Robustness Underpin Buy RatingNovember 1, 2024 | markets.businessinsider.comBombay Bicycle Club, The Cribs and more to join The Maccabees at huge All Points East 2025 gigOctober 30, 2024 | uk.news.yahoo.comBicycle Therapeutics plc (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) have received an average rating of "Moderate Buy" from the nine ratings firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating on theOctober 27, 2024 | marketbeat.comBicycle Therapeutics: Innovative Pipeline and Promising Developments Justify ‘Buy’ RatingOctober 25, 2024 | markets.businessinsider.comOppenheimer Remains a Buy on Bicycle Therapeutics (BCYC)October 25, 2024 | markets.businessinsider.comBicycle Therapeutics (BCYC) Receives a Buy from BarclaysOctober 25, 2024 | markets.businessinsider.comBicycle Therapeutics (BCYC) Receives a Buy from BarclaysOctober 25, 2024 | markets.businessinsider.comBicycle Therapeutics' (BCYC) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $38.00 target price on shares of Bicycle Therapeutics in a report on Thursday.October 24, 2024 | marketbeat.comBicycle Therapeutics announces presentation of MT1-MMP dataOctober 23, 2024 | markets.businessinsider.comBicycle Therapeutics (NASDAQ:BCYC) Shares Down 5.8% - Here's What HappenedBicycle Therapeutics (NASDAQ:BCYC) Trading Down 5.8% - Here's WhyOctober 23, 2024 | marketbeat.comBicycle Therapeutics (BCYC): High-Growth UK Stock with Innovative Peptide TechnologyOctober 17, 2024 | msn.comBicycle Therapeutics (NASDAQ:BCYC) Sees Large Volume Increase - Here's WhyBicycle Therapeutics (NASDAQ:BCYC) Sees Unusually-High Trading Volume - Time to Buy?October 17, 2024 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Hits New 12-Month High - Should You Buy?Bicycle Therapeutics (NASDAQ:BCYC) Sets New 52-Week High - Still a Buy?October 16, 2024 | marketbeat.comBicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 CongressOctober 16, 2024 | finance.yahoo.comBicycle Therapeutics plc (NASDAQ:BCYC) Short Interest Up 12.3% in SeptemberBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) was the target of a large increase in short interest in September. As of September 30th, there was short interest totalling 2,650,000 shares, an increase of 12.3% from the September 15th total of 2,360,000 shares. Based on an average daily trading volume, of 327,600 shares, the short-interest ratio is presently 8.1 days.October 15, 2024 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Stock Position Raised by The Manufacturers Life Insurance CompanyThe Manufacturers Life Insurance Company increased its holdings in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 275.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 97,392 shares of tOctober 10, 2024 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Trading 3.5% Higher - Here's What HappenedBicycle Therapeutics (NASDAQ:BCYC) Shares Up 3.5% - Still a Buy?October 9, 2024 | marketbeat.comMarshall Wace LLP Buys Shares of 88,987 Bicycle Therapeutics plc (NASDAQ:BCYC)Marshall Wace LLP purchased a new position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 88,987 shares of the company's stock, valued at approximately $1,80October 6, 2024 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) CTO Michael Skynner Sells 972 SharesOctober 5, 2024 | insidertrades.comInsider Selling: Bicycle Therapeutics plc (NASDAQ:BCYC) CEO Sells 3,212 Shares of StockOctober 5, 2024 | insidertrades.comPoint72 Asset Management L.P. Has $1.18 Million Position in Bicycle Therapeutics plc (NASDAQ:BCYC)Point72 Asset Management L.P. lowered its position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 82.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 58,500 shares of the company's stock after selling 284,094 sharesOctober 4, 2024 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Given Average Recommendation of "Moderate Buy" by BrokeragesBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and seven have assigneOctober 2, 2024 | marketbeat.comFirst ever ‘Bicycle Rodeo’ held in StroudsburgOctober 1, 2024 | yahoo.comCubist Systematic Strategies LLC Buys 86,989 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)Cubist Systematic Strategies LLC boosted its stake in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 923.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor ownedOctober 1, 2024 | marketbeat.comPerceptive Advisors LLC Acquires Shares of 572,000 Bicycle Therapeutics plc (NASDAQ:BCYC)Perceptive Advisors LLC purchased a new position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 572,000 shares of the company's stock, valued at approximSeptember 30, 2024 | marketbeat.com Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late. BCYC Media Mentions By Week BCYC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCYC News Sentiment▼0.520.46▲Average Medical News Sentiment BCYC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCYC Articles This Week▼104▲BCYC Articles Average Week Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Immunic News Today Pieris Pharmaceuticals News Today Organon & Co. News Today ImmunityBio News Today Immunovant News Today Rhythm Pharmaceuticals News Today Apellis Pharmaceuticals News Today MoonLake Immunotherapeutics News Today Agios Pharmaceuticals News Today Verona Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCYC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide vic...Wide Moat Research | SponsoredThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of ...WealthPress | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
